Outcome of patients with human immunodeficiency virus on maintenance hemodialysis  by Ortiz, Carmen et al.
Kidney International, Vol. 34 (1988), pp. 248—253
CLINICAL INVESTIGATION
Outcome of patients with human immunodeficiency virus on
maintenance hemodialysis
CARMEN ORTIz, RUTH MENESES, DAVID JAFFE, JOHN A. FERNANDEZ, GUIDO PEREZ, and
JACQUES J. BOURGOIGNIE
Division of Nephrology, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
Outcome of patients with human immunodeficiency virus on mainte-
nance hemodialysls. Fifty-one adults with HIV infection, including 20
chronic hemodialysis patients with superimposed HIV infection and 31
patients with HIV-associated nephropathy requiring chronic mainte-
nance hemodialysis were followed to evaluate survival on outpatient
dialysis in relation to the clinical stage of the HIV infection. Regardless
of when they contracted the infection, AIDS patients who required
maintenance hemodialysis had a poor prognosis. All 17 patients who
developed AIDS died after a mean of 93 32 days on hemodialysis(median 30 days; range 2 to 540 days). On the other hand, 12 asymp-
tomatic HIV carriers were alive after a mean follow-up on chronic
hemodialysis of 488 75 days (median 420 days; range 142 to 850 days);
and five hemodialyzed patients with ARC were alive after 564 191
days (median 420 days; range 150 to 1230 days). The data confirm the
lack of effectiveness of maintenance hemodialysis for prolonging life in
patients with AIDS. This dismal prognosis was evident whether renal
failure antedated HIV infection or whether it was HIV-associated. In
asymptomatic HIV carriers and in patients with ARC, however, main-
tenance hemodialysis provides meaningful, long-term life support.
The growth of the human immunodeficiency virus (HIV)
epidemic and the sizeable number of patients developing renal
complications (6 to 10% in some centers) [1, 2] result in an
increasing need for providing dialysis to maintain life in HIV-
infected patients. As the prevalence of this devastating disease
expands, several important issues have been raised. Foremost
in the nephrologists' mind is how these patients fare on main-
tenance outpatient hemodialysis.
There is little information available on this issue, with the
exception of the dismal survival reported for patients with the
acquired immunodetIciency syndrome (AIDS) requiring chronic
hemodialysis. In the series of Rao, Friedman and Nicastri [1],
the median survival on bemodialysis of 31 patients with AIDS
developing irreversible renal failure was 1.4 months; only two
patients survived more than five months. Among another 18
patients maintained on chronic hemodialysis who developed
AIDS secondarily, no patient survived more than three months
[1]. In Miami, our experience is similar [2]. Sixteen inpatients
with AIDS and irreversible renal failure died 20.4 15,7 days
(range 2 to 60 days) after initiation of hemodialysis [21.
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In contrast, the outcome of asymptomatic HIV carriers and
patients with AIDS-related complex (ARC) requiring mainte-
nance hemodialysis is unknown. Preliminary observations sug-
gest that patients with ARC fare better than patients with AIDS.
Whereas six of 14 patients with ARC and chronic renal failure
died after a median survival of 180 days (range 120 to 330 days)
after initiation of hemodialysis, eight of 14 were alive after a
median period of 210 days [3]. Thus, the clinical stage of the
infection may be the important determinant of survival in
HI V-infected patients with chronic renal failure.
We report our experience and the outcome of 51 patients at
different clinical stages of HIV infection who needed chronic
maintenance outpatient hemodialysis.
Methods
Fifty-one patients with HIV infection requiring maintenance
hernodialysis in the outpatient facilities at the University of
Miami/Jackson Memorial Medical Center (46 patients) or at the
Miami Veterans Administration Medical Center (5 patients)
were prospectively followed. All patients entered the study
before July 31, 1987 and were followed until November 30, 1987
or time of death.
The definition of chronic maintenance dialysis corresponds to
that of HCFA: requirement of supportive dialysis therapy for at
least 30 days, discharge of the patients from inpatient services,
and continuation of dialysis in the outpatient setting. Routine
hemodialysis techniques were used with four hour treatments
performed thrice weekly, via a surgically-created vascular
access, using cuprophane dialyzers and bicarbonate or acetate
solutions of standard composition.
The inpatient and outpatient medical records of each patient
were reviewed for sex, age, race, nationality, risk factors, time
on chronic hemodialysis, time of diagnosis, staging of HIV
infection and progression to other stages or death. Causes of
renal failure and results of renal biopsies, and causes of death
and autopsies were reviewed, when available. On this basis,
two groups of patients were recognized. Group 1 included 20
patients on chronic hemodialysis who subsequently developed
HIV infection. Group 2 comprised 31 patients with HIV infec-
tion documented before or concurrently with the development
of symptomatic chronic renal failure necessitating dialytic in-
tervention. By and large, the former group included patients
with renal failure from a variety of nephropathies; whereas, the
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Table 1. Clinical data in HI V-infected adults on maintenance hemodialysis
8 Age at time of death or at last follow-up.b (H) means Haitian extraction.
C Risk factors for HIV infection are listed hierarchically in the following order: IVD for parenteral drug use, homo for homosexual or bisexual
men, hetero for women with heterosexual contacts with a partner with proven AIDS in the absence of other risk factor, blood for recipients of con-
taminated blood, and unknown for patients with none of the above risk factors identified. Patients with multiple risk factors are tabulated only in
the group listed first.d HIV+ indicates HIV seropositive asymptomatic carriers and patients with clinical ARC or AIDS.
Patient
Agea
yrs/sex Raceb
Risk
factore
HIV stage Duration
HIV+d
Time on
hemodialysis
Time on
hemodialysis
and HIV+Carrier ARC
days
AIDS
days Outcome
1Group
I 37/M Black IVD 150 180 9 339 390 339 Dead
2 45/M White Blood 810 — — 810 870 810 Alive
3 30/M Black IVD 180 — 540 720 1115 720 Dead
4 27/M Black (H) Unknown 720 — — 720 2670 720 Alive
5 49/M Black (H) IVD 330 — — 330 240 240 Dead
6 74/M White Unknown 690 — — 690 1095 690 Dead
7 35/M Black IVD 690 — 30 720 1825 720 Dead
8 53/M Black Unknown 240 — — 240 330 240 Alive
9 38/M Black Blood 850 — — 850 2310 850 Alive
10 59/M Black Unknown 130 720 — 850 1050 850 Alive
11 33/M Black IVD 840 — — 840 2675 840 Alive
12 34/F Black Unknown 51 — — 51 1825 51 Dead
13 48/M Black Blood 365 — — 365 365 365 Dead
14 41/F Black (H) Blood 142 — — 142 2675 142 Alive
15 26/F Black Unknown — 210 30 240 480 240 Dead
16 34/M Black IVD — 420 — 420 1110 420 Dead
17 32/M Black IVD — 238 2 240 240 240 Dead
18 37/M Black IVD — 60 90 150 120 120 Dead
19 27/M Black IVD - 420 — 420 1560 420 Alive
20 34/M White Blood — — 150 150 240 150 Dead
Mean 40 442 321 122 464 1159 458
3 81 82 62 201 63
Group 2
21 40/F Black IVD 300 — — 300 60 60 Alive
22 36/F Black IVD 90 — — 90 90 90 Alive
23 41/F Black Hetero 150 — 30 180 90 90 Dead
24 37/M Black IVD 390 — — 390 30 30 Dead
25 27/F Black (H) Unknown 420 — — 420 420 420 Alive
26 32/M Black IVD 360 — — 360 360 360 Dead
27 58/M Black (H) Unknown 420 — — 420 420 420 Alive
28 37/F Black IVD 450 30 — 480 300 300 Dead
29 35/M Black IVD 540 — — 540 540 540 Alive
30 37/F Black IVD 270 — — 270 270 270 Alive
31 28/M Black IVD 360 — — 360 360 360 Alive
32 33/F Black IVD 180 60 — 240 240 240 Dead
33 30/M Black IVD 240 — — 240 240 240 Alive
34 39/M Black IVD 240 — — 240 240 240 Dead
35 31/M Black IVD — 870 — 870 330 330 Dead
36 33/M Black IVD — 390 — 390 300 300 Alive
37 22/F Black (H) Unknown — 810 — 810 330 330 Dead
38 23/M Black (H) Unknown — 365 150 515 180 180 Dead
39 32/M Black IVD — 1230 — 1230 1230 1230 Alive
40 35/M Black Unknown — ISO — 150 150 150 Dead
41 37/F Black IVD — 78 12 90 90 90 Dead
42 36/M Black Homo — 216 14 230 230 230 Dead
43 36/M Black IVD — 240 30 270 240 240 Dead
44 231M Black (H) Unknown — 30 180 210 180 180 Dead
45 37/M Black Homo — 330 — 330 330 330 Dead
46 32/M Black (H) Unknown — 80 — 80 80 80 Dead
47 36/M Black (H) IVD — 1260 — 1260 150 150 Alive
48 33/M White IVD — — 240 240 21 21 Dead
49 48/M Black IVD — — 270 270 90 90 Dead
50 33/M Black (H) Unknown — — 30 30 30 30 Dead
51 37/M White Homo — — 210 210 180 180 Lost
Mean 35 315 409 116 378 251 251
5E 1 34 110 33 53 40 40
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Fig. 1. Initial and final HIV status and patient outcome for 5! adults on
maintenance hemodialysis.
latter was comprised of patients with HI V-associated nephrop-
athy. No patient received azidothymidine.
The diagnosis of HIV infection [formerly called human T-cell
lymphotropic virus Type III (HTLV-III) or lymphadenopathy-
associated virus (LAV)] was made according to criteria defined
by the CDC [4]. Prior to July 1985, diagnosis of HIV disorders
was documented clinically and supported by inverted T-cell
subset ratios. Since June 1985, evidence of circulating anti-HIV
antibodies has been required to establish the diagnosis. All
patients were evaluated serologically by enzyme linked immu-
nosorbent assay (ELISA) and by Western blot immunoelectro-
phoretic assay to identify antibodies to specific HIV antigens.
Three clinical stages of HIV infection were recognized cor-
responding to early CDC classification. The equivalence of this
earlier staging with the new CDC classification has been pub-
lished [3]. HIV carriers are asymptomatic seropositive patients
without clinical evidence of ARC/AIDS. They have been rec-
ognized only since June 1985. The syndrome of ARC is defined
by the presence of constitutional symptoms or physical findings
compatible with HIV infection. Included in ARC are patients
with recurrent fevers or diarrhea for thirty days without estab-
lished etiology, night sweats, weight loss greater than 10% body
weight, or generalized lymphadenopathy described as diffuse,
greater than one centimeter at two extra-inguinal sites, recur-
rent oral candidiasis or pulmonary mycobacterium tuberculo-
sis, and barring demonstration of opportunistic infections or
Kaposi's sarcoma characteristic of AIDS [5]. One patient (#47
in Table 1) with biopsy-proven lymphoplasmocytic interstitial
pneumonia was classified as ARC. AIDS is defined by the
presence of specific opportunistic infections or cancers defined
by CDC criteria with the diagnosis established by culture or
identification of the etiologic agent in body fluids, biopsy
specimens or samples obtained in vivo or post-mortem [61.
Disseminated mycobacterium tuberculosis was classified as
AIDS.
Risk factors were previously defined [6]. Patients were listed
hierarchically for risk factor in the following order: 1) parenteral
drugs use; 2) homosexual or bisexual men; 3) patients infected
heterosexually by partners known to have HIV infection; 4)
patients who received contaminated blood products; and 5)
patients including Haitians, with none of the above risk factors
identified.
Duration at any one stage was defined as the time, in days,
during which patients on maintenance hemodialysis remained at
Table 2. Causes of death
HIV Patients with Patients with
Carriers ARC AIDS
Cerebrovascular accident 3 — —
Sepsis 2 2 6 (Opportunistic)
Pneumonia — 2 —
Uremia — 1 1
Failure to thrive — 2 5
Encephalopathy — — 4
Other 2 1 1
that infective stage before progression to another stage, termi-
nation of hemodialysis, death or completion of the study.
Results are reported as means SE, median and range.
Statistics were performed on a Hewlett-Packard model 85
microcomputer using Student's (-test for unpaired data.
Results
Table 1 presents selected clinical data for the 51 chronic adult
hemodialysis patients with HIV infection. Mean age was 36.6
1.3 years (range 22 to 74 years). Thirty-nine patients were male,
5 were white, and 46 were black of whom 11 were of Haitian
extraction. The primary risk factor, the duration of each clinical
stage of HIV infection, the total time with HIV infection, the
total time on hemodialysis, the time on hemodialysis with HIV
infection and the patient outcome are listed. Initial and final
HIV status and patient outcome are illustrated in Figure 1.
Causes of death are listed in Table 2.
Twenty-eight patients were initially diagnosed as asympto-
matic seropositive HIV carriers (Fig. 1). Twenty-one of them
remained asymptomatic and 14 were alive after a mean fol-
low-up of 429 75 days (median 380 days; range 60 to 850 days)
of maintenance hemodialysis. Two HIV carriers (patients #21
and 22 of Table 1) recovered renal function after 60 and 90 days,
respectively. Excluding these two patients, survival of alive
carriers (N = 12) averaged 488 75 days (median 420 days;
range 142 to 850 days) on chronic hemodialysis. Seven patients
died of non-HIV related causes, including myocardial infarction
(1), cerebrovascular accident (3), sepsis with "non-opportun-
istic" organisms (2) or dialysis accident (1), after an average of
282 84 days (median 240 days; range 51 to 690 days) of
chronic hemodialysis and HIV infection (Table 2). Four pa-
tients progressed to ARC and three to AIDS after 276 81 days
(median 180 days; range 51 to 690 days) of chronic hemodialy-
sis.
Seventeen patients had an initial diagnosis of ARC (Fig. 1).
This group was augmented by four patients whose clinical
status evolved from asymptomatic HIV carrier to ARC. Five
patients were alive after 564 191 days (median 420;range 150
to 1230 days) of chronic hemodialysis and ARC. Eight patients
died after 215 54 days (median 235; range 30 to 720 days) of
maintenance hemodialysis and ARC. Deaths resulted from
sepsis (2), pneumonia (2), failure to thrive (2), suspected drug
overdose (1). One patient elected to stop dialysis and died of
uremia (Table 2). Eight of the 21 patients with ARC developed
AIDS after 179 35 days (median 210; range 30 to 365 days).
An initial diagnosis of AIDS was present in six patients (Fig.
1). One patient was lost to follow-up after 180 days of chronic
hemodialysis and AIDS and was presumed dead. The other
Carrier. 28 21 ... 14 Alive
3 4
ARC... 13 ... 5 Alive
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patients died after 21, 30, 90, 150 and 180 days of chronic
hemodialysis and AIDS. This group was increased by 11
patients whose initial clinical status evolved from asymptomatic
carrier (N 3) or ARC (N = 8). All 17 patients with AIDS died
after a mean of 93 32 days (median 30; range 2 to 540 days) on
hemodialysis after the diagnosis of AIDS was made. All pa-
tients died within six months except one (patient #3 of Table 1),
who survived 540 days with disseminated mycobacterium tu-
berculosis. Causes of death included opportunistic infections
characteristic of AIDS (6), failure to thrive (5), encephalopathy
(4), or uremia (1) (Table 2).
The overall mean, SE, and median duration on maintenance
hemodialysis of each clinical stage of HIV infection is illus-
trated in Figure 2. Twenty-eight HIV carriers remained asymp-
tomatic for 345 48 days (median 243 days), 21 patients had
ARC for 275 60 days (median 243 days), 17 patients had AIDS
for 93 32 days (median 30 days). Whereas, the differences
between HIV carriers and patients with ARC were not statisti-
cally significant, survival for patients with AIDS was signifi-
cantly shortened (P < 0.001 vs. carriers and P < 0.02 vs.
patients with ARC).
To determine if the infection with HIV affected outcome
differently in different chronic dialysis populations, the 51
patients were divided into two groups on the basis of their past
medical history and HIV status at the time renal failure was
diagnosed and chronic hemodialysis initiated. Group 1 included
20 patients who developed renal failure as a result of various
non-HIV-associated nephropathies and became HIV infected
secondarily after initiation of hemodialysis. Group 2 comprised
31 patients whose renal failure was recognized concomitantly
with or after a diagnosis of HIV infection was made.
Primary risk factors for groups 1 and 2 are listed in Table 3.
Intravenous drug use was the most common risk factor in each
group with an overall incidence of 55 percent. Blood transfu-
sions were a risk factor only in patients with primary renal
disease. Two of these five patients (patients #2 and 9 of Table
I) were contaminated in preparation of or at the time of renal
Table 3. Risk factors in 51 HIV-infected adults on chronic outpatient
hemodialysis
Group 1 Group 2
Renal patients HIV patients
developing developing
HIV infection renal failure
Risk factora secondarily secondarily Total
Lv. Drug use 9 19 28
Blood transfusions 5 0 5
Homosexuality 0 3 3
Heterosexuality 0 1 1
Haitians 1 7 8
Unknown 5 1 6
20 31 51
AIDS... 7.0 Alive
Fig. 3. Outcome of adult chronic hemodialysis patients with primary
renal disease and secondary HIV infection (N = 20).
transplantation, rejected the transplanted kidney after a few
months and returned to chronic hemodialysis [7]. In contrast,
HIV patients who later developed renal failure included three
patients infected homosexually, one patient infected hetero-
sexually and seven Haitians, a group in which HIV contamina-
tion occurs mainly heterosexually [8]. Five non-Haitian patients
of Group I had no identified risk factor. They had been on
chronic hemodialysis from 3 to 59 months before HIV infection
was documented. All were transfused and may have been
contaminated by blood. Multiple risk factors were present in
two homosexuals and in two Haitians who were also i.v. drug
users and in one Haitian who received contaminated blood.
Figure 3 illustrates the HIV status and the outcome of 20
patients with chronic renal failure consequent to various forms
of renal disease who secondarily developed HIV infection
(group 1). These patients had been on maintenance hemodialy-
sis for an average of 701 181 days (median 1115; range 120 to
2675 days) before the infection was recognized. Then, 14
patients were asymptomatic HIV carriers, five patients had
ARC and one patient had AIDS. Ultimately, 10 patients re-
mained asymptomatic, four of whom died, three had ARC, one
of whom died, and seven had AIDS, all of whom died. Six
asymptomatic HIV carriers were alive on chronic hemodialysis
600 131 days (median 780; range 142 to 850 days) after
diagnosis of HIV infection. Two HIV carriers developed ARC
and two progressed onto AIDS after an average of 287 135
days (median 180; range 130 to 690 days). Two of the seven
patients with ARC were alive on hemodialysis after 420 and 720
500 -
400
300
200
100 - I
P<0.02
*— P<0.001
ARC
(N = 21)
Carrier
(N = 28) AIDS(N = 17)
Fig. 2. Duration on maintenance hemodialysis of each clinical stage of
HIV infection. Solid lines indicate means sE; broken lines indicate
medians.
a Risk factors are listed hierarchically (Table I legend).
Carrier... 14 10 . . . 6 Alive
2 2
ARC...5 3...2AIive
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days, one patient died, and four developed AIDS. The seven
patients who eventually developed AIDS died an average of 122
72 days (median 30; range 2 to 540 days) after the diagnosis
was made.
Figure 4 depicts the outcome for 31 HIV infected patients
whose clinical course was complicated by or associated with
chronic renal failure. In 18 of 31 patients, chronic renal failure
and HIV infection were diagnosed simultaneously; whereas, in
13, HIV infection preceded the need for chronic hemodialysis
by 298 81 days (median 219 days; range 30 to 1110 days). HIV
status at the time of initiation of chronic hemodialysis included
14 asymptomatic HIV carriers, 12 patients with ARC and five
patients with AIDS. Ultimately, 11 patients remained asympto-
matic, three of wh',m cied, 10 patients had ARC, seven of
whom died, IJ patients had AIDS, all of whom died. Eight
HIV carriers were alive 300 59 days (median 315; range 60 to
540 days) after initiation of maintenance hemodialysis. Three
HIV carriers progressed to ARC or to AiDS after 150, 180 and
450 days. Three of 14 patients who developed ARC were alive
after 150, 300 and 1230 days on hemodialysis; whereas, seven
died after 187 52 days (median 140; range 30 to 330 days) and
four progressed to AIDS. The 10 patients with AIDS died after
a mean follow-up on hemodialysis of 74 22 days (median 30;
range 12 to 180 days).
The duration on chronic hemodialysis of each clinical stage of
HIV infection was not different between the two groups (Table
4).
Discussion
Survival in patients infected with HIV is foreshortened once
AIDS develops, varying with the type of opportunistic infection
and/or cancer responsible for the diagnosis. In patients, mainly
homosexuals with Kaposi's sarcoma and no opportunistic in-
fection, survival ranges from 14 to 30 months; whereas, in
AIDS patients with opportunistic infection(s), the time course
between diagnosis of AIDS and death is shortened to 4 to 10
months [9].
The occurrence of irreversible renal failure carries a grave
prognosis in patients with AIDS and further reduces their
survival. Rao et al [1] recently described the outcome of
patients with AIDS and irreversible renal failure requiring
hemodialysis. In one series of 43 patients with AIDS and
irreversible renal failure, 12 patients were not dialyzed and died
of renal failure; 31 were hemodialyzed, but 26 of them survived
less than three months. In another group of 18 patients who
HIV stage
Carrier ARC AIDS
Group 1
Number 14 7 7
Mean SE 442 83 321 83 122 72
Median 348 238 30
Range 51—850 30—720 2—540
Group 2
Number 14 15 10
Mean SE 255 41 252 81 74 22
Median 255 165 30
Range 30—540 30—1230 12—180
developed AIDS during maintenance hemodialysis, none sur-
vived more than three months. Thus, overall only five of 62
patients with AIDS and irreversible renal failure survived more
than three months [1].
Our experience is similar in patients with AIDS originating
from a comparably low socio-economic, inner city patient
population where i.v. drug usage is prevalent. Of 51 patients
with HIV infection and irreversible renal failure, 12 (or 24%), all
patients with AIDS were not dialyzed because of hemodynamic
instability and/or patient choice; sixteen of the remaining 39
patients never left the inpatient services and died of AIDS after
20.4 15.7 days (range 2 to 60 days), despite bemodialysis
treatment; the remaining 23 HIV-infected patients, mostly
asymptomatic HIV carriers and patients with ARC eventually
left the hospital to join an outpatient maintenance hemodialysis
program [2].
The present report extends these previous observations to
consider patients with different clinical stages of HIV infection
in the outpatient dialysis setting, that is, patients who were well
enough to survive 30 days of suprortive hemodialysis treatment
defining chronic hemodialysis for HCFA and to join an outpa-
tient dialysis program. It confirms the dismal prognosis of
patients with AIDS on maintenance hemodialysis. The latter is
true whether hemodialysis was required as a consequence of
renal failure developing in patients with AIDS or whether AIDS
developed secondarily in patients previously receiving mainte-
nance hemodialysis for "non-HIV associated" nephropathies.
All 17 patients who developed AIDS on chronic hemodialysis
died after a mean 93 days and a median 30 days after the
diagnosis of AIDS was made. Except for one patient with
disseminated tuberculosis who survived 540 days on chronic
hemodialysis, all patients with AIDS were dead within nine
months, and only five of 17 survived more than three months on
hemodialysis.
This series of patients with AIDS is too small; more experi-
ence is needed to identify categorically which specific compli-
cations may carry a worse prognosis and which, if any, may be
compatible with a meaningful survival on hemodialysis. Mor-
tality was not limited to patients with a specific risk factor for
HIV infection. The rapid demise of patients with AIDS after
initiation of hemodialysis raises the question whether hemodi-
alysis per se, its hemodynamic consequences, the type of
membrane used, heparinization or other events associated with
Carrier... 14 11 . . . 8 Alive
1 2
ARC
Table 4. Mean SE, median and range, duration on chronic
hemodialysis of each clinical stage of HIV infection for Group 1 and
Group 2
10... 3 Alive
AIDS.
Fig. 4. Outcome of adult chronic hemodialysis patients with primary
HIV infection associated with chronic renal failure (N = 31).
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hemodialysis may accelerate the fatal outcome of patients with
AIDS.
In contrast, the data indicate that patients with irreversible
renal failure who carry the HIV virus, as indicated by the
presence of circulating anti-HIV antibodies, and patients with
ARC survive longer on maintenance hemodialysis than patients
with AIDS. The increased survival was evident whether renal
disease was primary with superimposed HIV infection, or
whether the renal disease was originally associated with HIV
infection. Two patients improved renal function sufficiently to
terminate dialysis and their study participation was discontin-
ued at that point. At last follow-up, 12 HIV carriers and five
patients with ARC were alive on maintenance hemodialysis
after mean follow-ups of 488 75 days and 564 191 days,
respectively.
Nevertheless, the mortality on hemodialysis of HIV carriers
and patients with ARC is intriguing and of concern as it far
exceeds the mortality observed among our non-HIV paiients,
20 to 50 years old, currently on chronic hemodialysis. Seven of
21 HIV carriers and eight of 13 patients with ARC died. Deaths
were associated with sepsis in two (both i.v. drug users) and
with a cerebrovascular accident in three HIV carriers (2 i.v.
drug users), an unusual cause of death in a young adult
population. Two patients with ARC (both i.v. drug users) also
died of sepsis with "non-opportunistic" organisms and two
exhibited the syndrome of failure to thrive described in patients
with AIDS on chronic hemodialysis [1]. This high mortality may
result from continued i.v. drug use by some patients. It may
also reflect the strict criteria applied for making a diagnosis of
AIDS. Some patients carrying a clinical diagnosis of ARC likely
died of complications which would have categorized them as
having AIDS but remained unrecognized in the absence of
systematic autopsies.
The data also indicate that HIV infection progresses in
patients maintained on chronic outpatient hemodialysis. Where-
as only 6 of 51 patients (12 percent) had AIDS initially, 17 of
them (33 percent) eventually died of complications of AIDS
after a mean follow-up on chronic hemodialysis of 225 50
days with HIV infection. It is our impression that HIV may
progress faster in patients on maintenance hemodialysis than in
HIV-infected patients without renal failure. An answer to this
important question, however, must await the results of longer
investigations performed in a larger study group than the
present one.
Hopefully, our observations will help enlighten the distraught
atmosphere which currently exists about patients with HIV
infection and irreversible renal failure. We agree with the
conclusions of Rao et al [1] that hemodialysis is not effective in
prolonging life in patients with AIDS and irreversible renal
failure. "Renal failure in this context is only the signpost of
inexorable patient disintegration" [1]. We also emphasize their
belief that room for individualization of therapy must exist,
taking into consideration the expected quality of life, the need
for recurrent hospitalizations and the hemodynamic challenges
of hemodialysis in a debilitated patient. On the other hand, the
results of the present study suggest that maintenance dialysis
should be performed in HIV carriers and patients with ARC.
Should progression occur from ARC to AIDS, discussions
should be held with the patient in advance to guide further
interventions. We strongly recommend that HIV infected pa-
tients be fully instructed and maintain an active role in deciding
dialytic interventions and alternatives. The possible advent of
future therapies that may eventually impact directly on HIV
infection, its complications and progression should also be
considered.
Research is needed to uncover potential clinical and immu-
nologic markers of progression of disease to help recognize and
differentiate which patients may remain quiescent as HIV
carriers from those who will progress to symptomatic stages of
HIV infection.
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